Early C‐reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150:atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–873.
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.0393
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016
   PubMed Web of Science ®Google Scholar
• Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6. doi:10.1038/s41698-018-0048-z
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.
   PubMed Web of Science ®Google Scholar
• Pocino K, Stefanile A, Basile V, et al. Cytokines and hepatocellular carcinoma: biomarkers of a deadly embrace. J Pers Med. 2022;13(1):5. doi:10.3390/jpm13010005
   PubMed Web of Science ®Google Scholar
• Pathak A, Agrawal A. Evolution of C-reactive protein. Front Immunol. 2019;10:943. doi:10.3389/fimmu.2019.00943
   PubMed Web of Science ®Google Scholar
• Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1):301. doi:10.1186/s12916-022-02506-x
   PubMed Web of Science ®Google Scholar
• Socha MW, Malinowski B, Puk O, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164(103419):103419. doi:10.1016/j.critrevonc.2021.103419
   PubMedGoogle Scholar
• Machado D, Marques C, Dias M, Campainha S, Barroso A. Inflammatory prognostic biomarkers in advanced non-small cell lung cancer. Pulmonology. 2019;25(3):181–183. doi:10.1016/j.pulmoe.2019.02.007
   PubMed Web of Science ®Google Scholar
• Suzuki S, Katagiri R, Yamaji T, et al. Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort. Br J Cancer. 2022;126(10):1481–1489. doi:10.1038/s41416-022-01715-8
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Kakizaki S, Hiraoka A, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int. 2022;16(5):1150–1160. doi:10.1007/s12072-022-10358-z
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Amano Y, Kanata K, et al. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Med Oncol. 2019;36(4):33. doi:10.1007/s12032-019-1255-3
   PubMed Web of Science ®Google Scholar
• Riedl JM, Barth DA, Brueckl WM, et al. C-Reactive Protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study. Cancers. 2020;12(8):2319. doi:10.3390/cancers12082319
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu L, He Z, et al. C-reactive protein levels predict responses to PD-1 inhibitors in hepatocellular carcinoma patients. Front Immunol. 2022;13:808101. doi:10.3389/fimmu.2022.808101
   PubMed Web of Science ®Google Scholar
• Kijima T, Yamamoto H, Saito K, et al. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021;70(3):657–665. doi:10.1007/s00262-020-02709-2
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Saito K, Yuasa T, et al. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2017;22(6):1081–1086. doi:10.1007/s10147-017-1166-2
   PubMed Web of Science ®Google Scholar
• Fukuda S, Saito K, Yasuda Y, et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021;9(2):e001564. doi:10.1136/jitc-2020-001564
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–1379. doi:10.1007/s00262-022-03349-4
   PubMed Web of Science ®Google Scholar
• Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7(1):113–123. doi:10.1001/jamaoncol.2020.3381
   PubMed Web of Science ®Google Scholar
• Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced Hepatocellular carcinoma. Clin Cancer Res. 2020;26(18):4795–4804. doi:10.1158/1078-0432.CCR-19-3884
   PubMed Web of Science ®Google Scholar
• Tian S, Chen Y, Zhang Y, et al. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2023;37(1):e24823. doi:10.1002/jcla.24823
   PubMed Web of Science ®Google Scholar
• Ma LN, Liu XY, Lu ZH, et al. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol Lett. 2017;13(5):3457–3464. doi:10.3892/ol.2017.5890
   PubMed Web of Science ®Google Scholar
• Toide M, Saito K, Yasuda Y, et al. Prognostic significance of c-reactive protein in patients with non-metastatic papillary renal cell carcinoma: results from the INternational Marker Consortium for Renal Cancer (INMARC) cohort. Clin Genitourin Cancer. 2022;20(4):e276–e282. doi:10.1016/j.clgc.2022.03.004
   PubMed Web of Science ®Google Scholar
• Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med. 2022;54(1):1339–1349. doi:10.1080/07853890.2022.2070660
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang D, Zeng H, et al. Inflammation-based scores predict responses to PD-1 inhibitor treatment in intrahepatic cholangiocarcinoma. J Inflamm Res. 2022;15::5721–5731. doi:10.2147/JIR.S385921
   PubMed Web of Science ®Google Scholar
• Huang J, Baum Y, Alemozaffar M, et al. C-reactive protein in urologic cancers. Mol Aspects Med. 2015;45:28–36. doi:10.1016/j.mam.2015.04.001
   PubMed Web of Science ®Google Scholar
• Gao B, Jeong W-I, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2007;47(2):729–736. doi:10.1002/hep.22034
   Web of Science ®Google Scholar
• Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42(11):1112–1140. doi:10.1002/cac2.12345
   Web of Science ®Google Scholar
• Suthen S, Lim CJ, Nguyen PHD, et al. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022;76(5):1329–1344. doi:10.1002/hep.32419
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–1690. doi:10.3390/cancers6031670
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801. doi:10.3390/ijms22115801
   PubMed Web of Science ®Google Scholar
• Sung PS. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(3):333–350. doi:10.3350/cmh.2021.0308
   PubMed Web of Science ®Google Scholar
• Zheng H, Peng X, Yang S, et al. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Cell Death Discov. 2023;9(1):65. doi:10.1038/s41420-023-01356-7
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–527. doi:10.1053/j.gastro.2013.01.002
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–2023. doi:10.1111/liv.14220
   PubMed Web of Science ®Google Scholar
• Nakayama T, Saito K, Kumagai J, et al. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151–e1158. doi:10.1016/j.clgc.2018.07.027
   PubMed Web of Science ®Google Scholar